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ABSTRACT
Introduction: Prostate cancer is common and the
incidence is increasing, but more men are living longer
after diagnosis, and die with their disease rather than
of it. Nonetheless, specific and substantial physical,
sexual, emotional and mental health problems often
lead to a poor quality of life. Urology services
increasingly struggle to cope with the demands of
follow-up care, and primary care is likely to play the
central role in long-term follow-up. The present phase
II trial will evaluate the feasibility and acceptability of a
nurse-led, person-centred psychoeducational
intervention, delivered in community or primary care
settings.
Methods and analysis: Prostate cancer survivors
diagnosed in the past 9–48 months and currently
biochemically stable will be identified from hospital
records by their treating clinician. Eligible men would
have either completed radical treatment, or would be
followed up with prostate specific antigen monitoring
and symptom reporting. We will recruit 120 patients
who will be randomised to receive either an augmented
form of usual care, or an additional nurse-led
intervention for a period of 36 weeks. Following the
health policy in Wales, the intervention is offered by a
key worker, is promoting prudent healthcare and is
using a holistic needs assessment. Outcome measures
will assess physical symptoms, psychological well-
being, confidence in managing own health and quality
of life. Healthcare service use will be measured over
36 weeks. Feedback interviews with patients and
clinicians will further inform the acceptability of the
intervention. Recruitment, attrition, questionnaire
completion rates and outcome measures variability will
be assessed, and results will inform the design of a
future phase III trial and accompanying economic
evaluation.
Ethics and dissemination: Ethics approval was
granted by Bangor University and North Wales REC
(13/WA/0291). Results will be reported in peer-reviewed
publications, at scientific conferences, and directly
through national cancer and primary care networks.
Trial registration number: ISRCTN 34516019.
INTRODUCTION
Prostate cancer is the most common cancer
for men in the UK (second worldwide), and
many survivors experience long-lasting phys-
ical and psychological needs. Over the past
20 years, in the UK, incidence rates have
doubled, but mortality rates have dropped by
a quarter.1 2 Common physical symptoms are
related to sexual function, urinary incontin-
ence,3 bowel symptoms,4 hot ﬂushes and the
risk of bone fracture.5 The management of
chronic comorbid conditions (eg, cardiovas-
cular disease and cerebrovascular disease,
Strengths and limitations of this study
▪ The intervention is designed in line with new
Welsh health policy by promoting prudent
healthcare principles and offering a key worker
for each cancer survivor.
▪ The holistic needs assessment uses novel and
comprehensive instruments bridging research
and hospital best practice, which will be shared
with patients, primary and secondary care.
▪ The study adopts an augmented form of usual
care, in line with ongoing developments of the
care system in the recruitment area.
▪ The intervention is offered to stable survivors,
irrespective of risk-stratification, or self-reported
level of need, for an accurate assessment of its
overall effectiveness.
▪ Recruitment area covers rural as well as urban
regions, with a wide mix of socioeconomic strata.
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hypertension, diabetes) often further increases the level
of need, and about two-thirds of patients with prostate
cancer are expected to have at least one major
comorbidity.6–8 Psychological distress is also signiﬁcant,
and most prostate cancer survivors require prompt infor-
mation about treatment outcomes and its impact on
daily living.9 The diagnosis and treatment toxicities also
affect the patients’ immediate families,10 particularly
through psychological distress related to anxiety, depres-
sion11 12 and psychosexual problems.13 Thus, the assess-
ment and management of the adverse treatment effects,
related psychosocial needs (also affecting their partners)
and the impact on the management of other comorbid
conditions is, for many patients, complex and
prolonged.
Current usual care and evidence base
Patients with prostate cancer are normally followed up
in out-patient clinics in hospital for up to 5 years, to
monitor and manage the risk of recurrence, and the
physical symptoms following treatment.14 However,
current practice is not underpinned by robust evidence,
and is notoriously variable between hospitals.15 In the
absence of reliable empirical evidence, the National
Institute for Health and Care Excellence (NICE) guide-
lines recommend that unless signiﬁcant treatment com-
plications develop, after 2 years, their follow-up care
should take place out of hospital.16 However, recommen-
dations on the type of follow-up to be undertaken are
notably missing from the guidelines.
In the last decade and a half, attempts have been made
to address the lack of empirical evidence regarding the
efﬁcacy and cost-effectiveness of prostate cancer
follow-up. Early initiatives showed that by involving
primary and community care, the utilisation of specialist
care may be reduced, especially for the more elderly
patients.17 Also, patients perceive they receive more care
from the general practitioner (GP),18 while their quality
of life remains similar between hospital and primary care
follow-up. However, notable concerns were reported
about the continuity of care, the miscommunication
between hospitals and GPs and the integration of pros-
tate speciﬁc antigen (PSA) testing. A number of hospital-
based alternatives have been proposed, such as hospital
group clinics,19 nurse face-to-face and telephone
clinics20–22 and e-health technology based follow-up.23–25
Such approaches fail to address the issues about the cap-
acity and scope of specialist secondary care teams, which
may struggle to offer, assess and manage a holistic range
of physical, psychosocial and educational needs of
patients. Recently, improvements in e-health platforms
facilitating the communication between hospital and
primary care, especially surrounding the safe monitoring
of PSA levels and cancer recurrence, have revived efforts
to consider a primary-care-led model of follow-up.26
Nurse-led interventions have been consistently shown
to be effective in a range of diseases, from diabetes and
depression,27 28 to various cancers,29 and, more
speciﬁcally, when interventions were administered in
primary care settings.30 There is sufﬁcient literature
showing the gaps in care to argue for a more intensive
approach initially,31 and most emerging models include
a nurse-led assessment of needs. There is evidence that
increasing the participation of patients with cancer in
their own care can reduce their psychosocial and infor-
mation needs.32 Self-management is now accepted as a
potential solution for the complex needs of prostate
cancer survivors,33 but conclusive evidence is still
needed regarding the design and delivery of such
interventions.
Person-centred and prudent healthcare for prostate cancer
survivors
Despite a tradition of predominantly disease-centred
follow-up, the person-centred approach features highly
in the UK health policy agenda. The 2004 NICE guide-
lines34 recognised the complex needs of cancer survi-
vors, and the Cancer Reform Strategy35 set out to
understand and address them. In Wales, the govern-
ment’s Together for Health—Cancer Delivery Plan36
directed Health Boards to assign a Key Worker to assess
and record the clinical and non-clinical needs of cancer
survivors in a personalised care plan, and to ensure care
is coordinated between hospital and community. The
policy highlighted the need for new multidisciplinary
models of follow-up to be developed and evaluated.
Moreover, the Bevan Commission37 recommended the
application of prudent healthcare principles, such as:
(1) offering early interventions, (2) promoting self-
management and the coproduction of healthcare,
(3) involving community assets in order to reduce the
level of unmet need, (4) removing unnecessary pro-
cesses (especially the duplication of support services),
and (5) adopting services that achieve similar or better
patient outcomes, while using less expensive human and
technical resources. Thus, for prostate cancer follow-up,
the government health policy directs towards holistic
and person-centred care, delivered safely and at the
earliest opportunity, outside of hospital, with the aim of
empowering patients to take an active role in managing
and improving their health.
The present trial (TOPCAT-P) is directly addressing the
growing capacity challenges facing hospital based services
in the UK, by engaging primary and community care
soon after the end of prostate cancer treatment. The
pilot trial, PROSPECTIV,14 38 served as the basis for the
development of the present work. TOPCAT-P is expand-
ing the personalised nurse-led intervention being piloted
in PROSPECTIV in three signiﬁcant areas: (1) the inter-
vention (including the holistic needs assessment) is
being offered irrespective of the patient-reported level of
need; (2) the care planning documentation and sharing
are updated in response to on-going changes to policy
and practice; (3) all participants in the intervention and
control arms will receive Macmillan written materials
as part of usual practice. The manualised nurse-led
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psychoeducational intervention includes an exploratory
and person-centred holistic needs assessment, promotes
self-management of symptoms, is delivered out-of-
hospital and includes patients’ partners, carers, or close
family members, where necessary. The aim of the current
pilot trial is to evaluate the feasibility and acceptability of
the intervention, addressing the wider group of cancer
survivors, using the novel holistic needs assessment and
care planning tools.
METHODS AND ANALYSIS
Trial design
TOPCAT-P is a randomised two-arm parallel-group
phase II external feasibility trial, comparing the effective-
ness and cost-effectiveness of a personalised, nurse-led,
psychoeducational intervention versus the augmented
version of usual care beginning to be delivered in North
Wales. The present trial follows the new Medical
Research Council (MRC) guidelines for the development
of complex interventions39 by investigating the feasibility
and acceptability of the intervention, the novel holistic
needs assessment instruments, and enhanced informa-
tion documenting and sharing procedure. This will be
used to inform the design of a phase III trial, which will
assess the effectiveness and cost-effectiveness of the
intervention.
Participant recruitment and consent
Inclusion criteria
The Urology Clinical Nurse Specialist will identify bio-
chemically stable incident patients with prostate cancer,
9–48 months postdiagnosis, from the multidisciplinary
team (MDT) records in the Wrexham Maelor Hospital.
They would have either received radical curative treat-
ment (surgery, radiotherapy, or hormone therapy), or
be followed up with PSA monitoring and symptom
reporting, but deemed unlikely to receive curative treat-
ment (watchful waiting). Notably, patients currently fol-
lowed up in the hospital or in the community will be
invited to participate in the study.
Exclusion criteria
The study will exclude men suitable for curative treat-
ment, but who choose to be monitored until proof of
further progression (active surveillance). Also, palliative
patients who are in the terminal stage of their disease or
who lack the capacity to consent (as assessed by the
referring clinician) will not be included.
Sample size
We intend to invite 300 patients to take part in the pilot
trial and estimate a recruitment rate of approximately
40%. This will allow the recruitment of 120 participants
(60 per trial arm—optimum for the randomisation pro-
cedure described below).40 A maximum attrition rate of
50% will ensure at least 30 patients per arm will com-
plete the trial. This will provide a satisfactory number of
participants for estimating the variation within the
sample (ie, the SD of the outcome measures), in order
to inform the power calculation for a future phase III
trial, which would be powered to detect clinically
relevant changes in prostate-related health and cost-
effectiveness.
Randomisation
Participants will be randomised individually to one of
the two arms of the trial (usual care or nurse-led inter-
vention), on a 1:1 basis and stratifying for age (65 or
under, 66–72, 73–80, over 80), according to the Cancer
Incidence Report 2007–2011.41 The concealed alloca-
tion procedure will use a secure, off-site electronic
system managed by the North Wales Organisation for
Randomised Trials in Health (NWORTH)—a UKCRC
fully registered trials unit. The system uses a sequential
dynamic adaptive randomisation algorithm,40 tuned to
balance within stratiﬁcation levels and overall, while
maintaining an acceptable level of unpredictability.
Augmented usual care
Patients in both arms of the study will continue to
receive the usual care delivered outside of the trial,
including any follow-up appointments (at the hospital or
general practice). To account for the variable patterns of
follow-up care, all contacts with healthcare professionals
will be recorded in bespoke health service-use diaries
(client service receipt inventory (CSRI)). To reﬂect the
changes to usual care being implemented in Wales, all
patients will be offered, in person, after providing
informed consent (see online supplementary appendi-
ces 1 and 2), a Macmillan Organiser42 to help self-
record and monitor any physical and psychological
symptoms, as well as the results of relevant medical tests
and medication taken. All patients will also be sign-
posted to contact the local Macmillan information
centre for information and advice regarding any cancer-
related concerns, as well as to contact their GP or hos-
pital team, if necessary, for appropriate medical support.
Intervention
Supplementary to augmented usual care, patients in the
intervention arm will be offered an initial appointment
with the research nurse for a holistic needs assessment,
and tailored follow-up appointments, as appropriate.
Before the start of the intervention, the research nurse
will complete the 2-day course, ‘The detection of psycho-
logical distress in patients with cancer’, needed for
National Health Service (NHS) staff to qualify at level 2
of the 4-tier model of Psychological Support.34 43
Additionally, through the Macmillan network, the nurse
will complete three training modules routinely recom-
mended for clinical staff delivering holistic needs assess-
ments: ‘Maguire Advanced Communication Skills’
training,44 ‘Motivational Interviewing’ and ‘10-min
CBT’.45 46 The intervention will make use of dynamic
personal care plans, and encourage self-management
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(empowering men to help themselves). Distinctly, the
research nurse will use a comprehensive holistic needs
assessment tool and care plan47—speciﬁcally exploring
physical, emotional, spiritual, lifestyle and family aspects
of cancer survivorship, together with an additional
bespoke instrument developed in secondary care to
monitor physical symptoms (H Nikkhouy-Toussi.
Consultant urological surgeon. Personal communica-
tion, 16 September 2013). Following the assessment, the
nurse will provide individualised information, advice and
support tailored to each patient, in order to help men
improve their symptoms or cope better with symptoms
they cannot improve. Patient referral to GP or secondary
care and signposting to community or third sector
support services will be made as appropriate. The holis-
tic needs assessment will be documented and shared
with patients and, following consent, with their GP.
If acute physical symptoms are identiﬁed or if disease
recurrence is suspected, these will be communicated dir-
ectly to the secondary care team and GPs. All referrals
to tertiary services will be documented in the secondary
care cancer network information system (CaNISC) to be
available to Oncology teams and facilitate seamless care
between healthcare providers.48
The initial holistic needs assessment
The ﬁrst appointment will be in person and will take
place out of hospital, in the patient’s own primary care
setting (by agreement with the general practice), at the
local community hospital, or, alternatively, in a dedicated
space at the research unit. Housebound patients will be
offered home visits. The needs assessment will explore a
comprehensive range of symptoms and concerns (see
table 1). The nurse will encourage patients to consider all
the aspects of survivorship, and will speciﬁcally explore
symptoms and concerns beyond the formalised checklist.
The delivery of the intervention is based on the novel
needs assessment instruments and care plan.47 49
Following the assessment, a range of person-tailored and
symptom-speciﬁc management strategies will be taught.
Physical and psychological needs will not be treated sep-
arately, but in relation to each other.50 Thus, physical
management techniques (eg, pelvic ﬂoor exercises,
double-void technique) will be taught in the context of
established cognitive-behaviour therapy techniques such
as self-monitoring, guided-discovery, life-style adjustment
and cognitive re-appraisal.51 The nurse will invite
patients to examine their lifestyle prior to their prostate
cancer diagnosis, identify how their thoughts, ideas,
Table 1 Summary of holistic needs assessment
Categories of need Symptom Summary of key assessment points
1. Physical symptoms 1. Pain Type of pain, duration and level of pain
2. Breathing problems Relevant comorbidities
3. Appetite Appetite levels, weight loss, soreness to the mouth, difficulties with
digestion, symptoms of nausea or vomiting
4. Urinary function Lower urinary tract symptoms, bleeding, incontinence concerns, impact on
everyday life (including psychological impact)
5. Bowel function Loose stools, bleeding or incontinence, impact on everyday life (including
emotional aspects)
6. Mobility Limitations to mobility, relations to fatigue, impact on mood, general
well-being and energy levels
7. Fatigue Dietary intake, impact on mood, enjoyment of daily activities, quality of
sleep, background stressors, fears or anxieties, relaxation therapies,
organisation of daily activities
8. Sexual function Erectile dysfunction, loss of libido, impact on relationship with partner,
patients’ and partner’s feelings, and anxieties
9. Hot flushes Emotional impact, participation in social activities, relations with others
2. Emotional concerns,
anxieties
1. Depression Low mood, loss of interest in everyday activities, depressive thoughts,
behaviour changes, isolation, social relations, utility of mood record
2. Anger Anger towards diagnosis, guilt at causing stress to partner or family, strain
on relationships
3. Fear of disease
recurrence
Lifestyle before diagnosis, hobbies, regular PSA monitoring
4. Altered body
image/sexuality
Weight gain/loss, breast swelling, impact on mood and sexuality,
behavioural changes, healthy nutrition, regular exercise
5. Spirituality Loss of faith, meaning of life after diagnosis
6. Financial concerns Loss of finance, insecurities about future earnings/costs, inability to afford
past hobbies, financial support
7. Lifestyle changes Travel insurance, planning of daily journeys, self-monitoring of symptoms
8. Memory and
attention
Increased overall stress, general self-confidence, change in sleep patterns
PSA, prostate specific antigen.
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feelings, attitudes and behaviours affect their day-to-day
life, and to reﬂect on the impact this is having on their
life. For patients who have fully adjusted to survivorship,
the process is expected to be relatively quick and seam-
less. However, patients who experience any level of
unmet need will ﬁrst beneﬁt from the guided self-
reﬂection.52 Second, where action is necessary to
address individual symptoms, patients will be offered
speciﬁc and personalised advice. Supported by the
nurse, patients will consider which aims and strategies
are attainable and relevant for their circumstances. A
plan will be devised together with the nurse to accom-
plish these goals, and will be documented in the perso-
nalised care plan. A copy of the initial holistic needs
assessment summary and the complete personalised
plan of care will be given to patients, and, with their
consent, will be sent to their GP for information and
long-term management. A covering letter will explain to
GPs the context of the care plan, the scope and duration
of the intervention, and will provide a point of contact
for any related queries. Where the level of support and
complexity of need will exceed the capability of the
current intervention, the nurse will speciﬁcally refer
patients to their GP or for specialist support, as
appropriate.
The follow-up sessions
By agreement with patients, the nurse will arrange
follow-up appointments to monitor the progress of the
self-management strategies advised during the initial
assessment. The progress made and any related patient
concerns will be documented in the patient’s plan of
care, and again shared with patients and their GP, as
before. The accompanying covering letter will inform
GPs of the remaining support available from the inter-
vention, and the outstanding patient needs and con-
cerns. Patients will also be given the opportunity to
request follow-up sessions at any point during the inter-
vention by contacting the nurse by telephone. As above,
follow-up appointments will take place in general prac-
tice, community hospital, the research unit, or at the
patient’s home, for housebound patients. These appoint-
ments will be in addition to any referrals to support
outside the intervention. We anticipate men will need
on average 1–2 follow-up sessions, but their number will
not be limited. The frequency, setting and content of
these sessions will be recorded by the nurse for the
process evaluation.
Outcome measures
As a phase II trial, the primary measures of interest are
patient recruitment, attrition and response rate for ques-
tionnaires. To capture the intervention outcome, a battery
of established patient reported measures will be used to
assess changes in the physical symptoms (Expanded
Prostate Cancer Index Composite, EPIC-26),53 psycho-
logical well-being (Hospital Anxiety and Depression Scale;
HADS),54 conﬁdence in managing own health,55 medical
and support needs (Supportive Care Needs Survey—
simpliﬁed response format),56 57 and general health and
quality of life (EuroQoL EQ-5D-5L),58 along with a
bespoke questionnaire assessing patients’ satisfaction with
the healthcare services. To reduce participant burden, the
questionnaires have been collated in a single booklet. All
questionnaires will be self-completed by patients. The
researcher recruiting the patients will offer the baseline
measures to all patients after consent, and prior to ran-
domisation. The researcher will remain blind to the ran-
domisation results until the end of recruitment.
Subsequent questionnaires will be sent by post to be com-
pleted by patients in both arms and similarly returned to
the research team by post (see table 2). The ongoing use
of health and social care services during the intervention
will be collected at 12, 24 and 36 weeks, using a purpose-
built diary. The questionnaire documents the frequency
and types of contacts with primary and secondary health-
care services, social services and voluntary sector services.
The diary will include information about: the number of
times the patient had to see a doctor, nurse, or other
healthcare professional in relation to his prostate cancer-
related symptoms; the special medication, aids and adapta-
tions prescribed to patients to help with their prostate
cancer-related symptoms; and the number of days patients
felt too unwell to participate in their normal activities due
to prostate cancer-related symptoms. Moreover, relevant
medical history data (eg, cancer diagnosis, stage, treat-
ment type, chronic and acute comorbid conditions, etc)
will be collected from GP-and hospital-held records with
patients’ consent.
A subsample of patients in the intervention group
(N=32), the research nurse and secondary and primary
care clinicians (N=10), will be invited to take part in
individual feedback interviews at the end of the trial.
Patients will be selected through purposive sampling to
include all types of treatment (surgery, radiotherapy,
hormone therapy, watchful waiting), cancer stage (loca-
lised, locally advanced/advanced), and represent a
balanced median split for age and level of need.
Clinicians will be selected from those who had the
largest number of patients in trial. A researcher not
involved in the intervention delivery will conduct
the interviews face-to-face, or alternatively by telephone.
The interviews will be semistructured and investigate the
patients’ experience of the intervention, the perceived
beneﬁts and missed opportunities of the trial, and pos-
sible effects beyond those captured in the proposed
outcome measures (both for patients and healthcare ser-
vices/clinicians).
Data safety and monitoring
The study procedure and intervention were assessed to
present only low impact risks for patient safety, with a
low probability. Thus, an independent data monitoring
group will not be needed, and interim analyses will not
be conducted. However, the intervention will be con-
tinuously monitored for safety by the research team,
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with direct input from the patients’ general practice and
referring secondary care clinicians. All process and
safety monitoring records will be maintained in accord-
ance with national and local research governance regula-
tions. All adverse events and serious adverse events will
be recorded, and followed up for the duration of the
study or until resolution. Assessment of adverse events
will be performed by the clinical lead of the research
team. All serious adverse events will be graded and
reported to the sponsor, funder, and the ethics and
research governance committees.
Data management
All data will be collected on paper questionnaires, which
will be stored, linked and entered electronically in an
anonymised format. Routine data checks will be per-
formed at two time points: (1) when the questionnaires
are received from patients, and (2) when the data are
entered into a secure electronic data capture system
(MACRO, V.4.2.4, InferMed Limited), hosted and
managed by the clinical trials unit (NWORTH).
Electronic data will be audited on an ongoing basis by two
independent auditors, and outcomes will inform the
remaining data collection and entry. All data queries will
be managed directly by a single Data Manager, and the
complete audit trail will be recorded electronically in
MACRO. At the end of the trial, all paper questionnaires
and electronic data will be archived securely and stored for
5 years, after which they will be conﬁdentially destroyed.
Data analysis
Feasibility metrics (eg, recruitment and retention rates,
clinical characteristics, randomisation, duration of the
intervention, etc) will be analysed ﬁrst, together with
adherence outcomes (patient acceptance and adherence
to the intervention). Medical history data will be assessed
for completeness in conjunction with the outcome mea-
sures. The semistructured interviews will be analysed
using the matrix based thematic Framework approach,
which facilitates analysis both by case and theme.59 60
A preliminary analysis of the intervention outcomes
will be carried out, following an intention-to-treat
approach. Point and 95% CI estimates will be calculated
for the changes in prostate-speciﬁc symptoms, quality of
life, psychological well-being, self-conﬁdence in man-
aging own health, and ongoing medical and support
needs between the two groups. Results will be used to esti-
mate SDs and effect sizes to help inform a sample size cal-
culation for a future phase III randomised control trial
(RCT)—if feasibility and acceptability are conﬁrmed.
The analysis will also address the health economics of
the intervention. The beneﬁt measurement will use both
generic health-related quality of life (EQ-5D-5L) and pros-
tate cancer speciﬁc quality of life measures. The analysis
will take a societal perspective, given the broad impact on
the NHS (both primary and secondary care), the patients,
their families and the third sector. In line with established
guidelines for economic evaluation of complex interven-
tions,61 the costing analysis will use the national unit
costs.62 The outcome of the preliminary economic analysis
estimates will serve to develop the protocol for a full
primary cost utility analysis, with a secondary cost–conse-
quence analysis, in a future phase III RCT.
DISCUSSION
The TOPCAT-P trial proposes a novel model of care for
prostate cancer survivors, in line with recent NICE
Table 2 Timeline of intervention delivery and outcome measures
Augmented usual care Nurse-led intervention
T0 T1 T2 T3 T0 T1 T2 T3
Consent 12 weeks 24 weeks 36 weeks Consent 12 weeks 24 weeks 36 weeks
Follow-up care
Macmillan organiser ✓ ✓
Routine signposting to
Macmillan information
centre, GP, hospital services
✓ ✓
Ongoing follow-up
appointments
✓ ✓
Holistic need assessment ✓
Follow-up appointments ✓
Outcome measures
EPIC-26, HADS, SCNS-34,
EQ-5D-5L, confidence in
managing own health,
satisfaction with healthcare
services
✓ ✓ ✓ ✓
Health service-use diary ✓ ✓ ✓ ✓ ✓ ✓
Feedback interview ✓
EPIC-26, Expanded Prostate Cancer Index Composite; GP, general practitioner; HADS, Hospital Anxiety and Depression Scale;
SCNS, Supportive Care Needs Survey.
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guidelines, local government health policy and charity
sector initiatives in Wales, to offer a holistic and persona-
lised care delivered in primary and community care set-
tings. These changes to presently hospital-based models
of care come in response to increased levels of patient
unmet need, raising numbers of prostate cancer survi-
vors with continuing upward estimates, and unavoidable
logistical and ﬁnancial pressures on secondary care
teams.
The present trial aims to evaluate the feasibility and
acceptability of the intervention, addressing the wider
group of cancer survivors, using the novel holistic needs
assessment and care planning tools, in the context of
care in Wales. The results will inform the design of a
deﬁnitive stage III trial, for this model of prostate cancer
follow-up. A phase III; RCT would be deemed feasible if:
(1) a minimum of 25% of the clinically eligible patients,
who will be invited to take part in the trial are recruited,
(2) the attrition rate during the trial is no greater than
20%, and (3) the outcome measures completion rate for
the active participants (ie, those who have not with-
drawn, died or been lost to follow-up) is above 66%. All
the feasibility metrics will be calculated using 95% CIs.
Moreover, the patients’ and clinicians’ feedback will be
used to assess the acceptability of the intervention and
shape its future administration as well as the overall com-
munication with participants and healthcare profes-
sionals. The recruitment, attrition and questionnaire
completion rates, together with the SD of the main
intervention outcomes will inform the estimation of the
sample size for a future phase III trial. The time needed
to collect and analyse the data will be used to determine
the optimum timings of each activity, and the overall
duration of the trial.
The nurse-led intervention piloted in TOPCAT-P is
based on a similar trial conducted in England
(PROSPECTIV),38 but is signiﬁcantly different in three
methodological areas, which will extend the knowledge
gained from PROSPECTIV, and assess the feasibility
and acceptability of the intervention in a different area,
and in different settings. First, the intervention is
offered to stable prostate cancer survivors irrespective
of their self-reported level of need. Second, the holistic
needs assessment, care planning and information
sharing documentation is based on novel instruments
currently being considered for routine clinical use in
the TOPCAT-P recruitment area. Third, the deﬁnition
of usual care is updated in response to on-going
changes to practice in Wales, including new routine
third sector improvements, which will provide a contex-
tualised assessment of the intervention’s effects.
However, similarly to PROSPECTIV, the intervention is
nurse-led, based on a psychoeducational framework,
promotes self-management of symptoms, is delivered in
the community and includes patients’ close social
group (eg, partner, family, carers), where this is rele-
vant and helpful for the patient.
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